Trial Profile
Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Salivary gland cancer
- Focus Adverse reactions
- 11 Dec 2023 Status changed from active, no longer recruiting to completed.
- 14 Jun 2023 Planned End Date changed from 31 Dec 2023 to 5 Nov 2023.
- 06 Jun 2023 Results assessing safety and activity of nivolumab (N) and ipilimumab (I)with palliative XRT presented at the 59th Annual Meeting of the American Society of Clinical Oncology